Arcus Biosciences, Inc.
RCUS
$10.53
$0.050.48%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 160.00M | 28.00M | 26.00M | 48.00M | 39.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 160.00M | 28.00M | 26.00M | 48.00M | 39.00M |
| Cost of Revenue | 139.00M | 122.00M | 101.00M | 123.00M | 115.00M |
| Gross Profit | 21.00M | -94.00M | -75.00M | -75.00M | -76.00M |
| SG&A Expenses | 29.00M | 28.00M | 28.00M | 30.00M | 30.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.00M | 150.00M | 129.00M | 153.00M | 145.00M |
| Operating Income | -8.00M | -122.00M | -103.00M | -105.00M | -106.00M |
| Income Before Tax | 0.00 | -112.00M | -93.00M | -92.00M | -93.00M |
| Income Tax Expenses | -- | -- | 1.00M | -- | -- |
| Earnings from Continuing Operations | 0.00 | -112.00M | -94.00M | -92.00M | -93.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.00 | -112.00M | -94.00M | -92.00M | -93.00M |
| EBIT | -8.00M | -122.00M | -103.00M | -105.00M | -106.00M |
| EBITDA | -6.00M | -119.00M | -100.00M | -103.00M | -104.00M |
| EPS Basic | -1.14 | -1.14 | -1.03 | -1.01 | -1.02 |
| Normalized Basic EPS | 0.00 | -0.71 | -0.63 | -0.63 | -0.64 |
| EPS Diluted | -1.14 | -1.14 | -1.03 | -1.01 | -1.02 |
| Normalized Diluted EPS | 0.00 | -0.71 | -0.63 | -0.63 | -0.64 |
| Average Basic Shares Outstanding | 106.10M | 98.40M | 91.70M | 91.40M | 91.10M |
| Average Diluted Shares Outstanding | 106.50M | 98.40M | 91.70M | 91.40M | 91.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |